Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis

Nephrology Dialysis Transplantation

Volumn 26, Issue 4, 2011, Pages 1173-1188

  Kim, Hyung Wook ^a   Lim, Ji Hee ^a   Kim, Min Young ^a   Chung, Sungjin ^a   Shin, Seok Joon ^a   Chung, Hyun Wha ^a   Choi, Bum Soon ^a   Kim, Yong Soo ^a   Chang, Yoon Sik ^a   Park, Cheol Whee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Akt protein kinase B; diabetic nephropathy; eNOS; nitric oxide; VEGF A VEGFR 2

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEXAPEPTIDE; HEXAPEPTIDE DRK6; INSULIN; MESSENGER RNA; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; HYPOXIA; INSULIN BLOOD LEVEL; KIDNEY MASS; MALE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RECEPTOR BLOCKING; TREATMENT DURATION;

ALBUMINURIA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-AKT; RENAL INSUFFICIENCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79953862219     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq610     Document Type: Article

References (52)

1. Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006; 2: 562-567 (Pubitemid 44465678)
2. Alsaad KO, Herzenberg AM. Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update. J Clin Pathol 2007; 60: 18-26 (Pubitemid 46142667)
3. Wolf G. New insights into the pathophysiology of diabetic nephro-pathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004; 34: 785-796 (Pubitemid 39657924)
4. Keane WF. The role of lipids inrenal disease: future challenges. Kidney Int 2000; 75: S27-S31 (Pubitemid 30205436)
5. Park CW, Kim HW, Ko SH et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 2006; 55: 885-893
6. Park CW, Kim HW, Ko SH et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238 (Pubitemid 46536909)
7. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017 (Pubitemid 38669987)
8. Feliers D, Chen X, Akis N et al. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int 2005; 68: 1648-1659 (Pubitemid 43169910)
9. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22 (Pubitemid 29038270)
10. Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17: 932-942
11. Kang DH, Hughes J, Mazzali M et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448-1457 (Pubitemid 32666327)
12. Sugimoto H, HamanoY, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-126083
13. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106: p32-p37 (Pubitemid 46920098)
14. Eremina V, Cui S, Gerber H et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735
15. Sison K, Eremina V, Baelde H et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010; 21: Epub ahead of print
16. Whittle C, Gillespie K, Harrison R et al. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci 1999; 97: 303-312 (Pubitemid 29425324)
17. Cha DR, Kim NH, Yoon JW et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000; 77: S104-S112
18. Nakagawa T, Kosugi T, Haneda M et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009; 58: 1471-1478
19. Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF-I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3-K signaling pathway. Nitric Oxide 2004; 10: 25-35 (Pubitemid 38410892)
20. De Vriese AS, Tilton RG, Elger M et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000 (Pubitemid 32378340)
21. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-3094
22. Schrijvers BF, Flyvbjerg A, Tilton RG et al. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21: 324-329 (Pubitemid 43159984)
23. Kim NH, Oh JH, Seo JA et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005; 67: 167-177 (Pubitemid 40019238)
24. Cha DR, Kim NH, Yoon JW et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000; 77: S104-S112
25. Baelde HJ, Eikmans M, Lappin DWet al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 2007; 71: 637-645 (Pubitemid 46494557)
26. Lindenmeyer MT, Kretzler M, Boucherot A et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic ne-phropathy. J Am Soc Nephrol 2007; 18: 1765-1776 (Pubitemid 46870313)
27. Hohenstein B, Hausknecht B, Boehmer K et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephro-pathy in man. Kidney Int 2006; 69: 1654-1661
28. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292: F1665-F1672 (Pubitemid 47105355)
29. Brosius FC III, Alpers CE, Bottinger EP et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45
30. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144 (Pubitemid 36578440)
31. Guo M, Ricardo SD, Deane JA et al. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 2005; 207: 813-821 (Pubitemid 43019739)
32. Bae DG, Gho YS, Yoon WH et al. Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 2000; 275: 13588-13596
33. Yoo SA, Bae DG, Ryoo JW et al. Arginine-rich anti-vascular endo-thelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol 2005; 174: 5846-5855
34. Park CW, Kim HW, Lim JH et al. Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 2009; 58: 2666-2676
35. Weibel ER. Practical methods for biological morphometry. Stereolo-gical Methods. London: Academic Press, 1979; 44-45
36. Bussolati B, Dunk C, Grohman M et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001; 159: 993-1008 (Pubitemid 32847190)
37. Sung SH, Ziyadeh FN, Wang A et al. Blockade of vascular endothe-lial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104 (Pubitemid 44707769)
38. Yamamoto Y, Maeshima Y, Kitayama H et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831-1840 (Pubitemid 38857042)
39. Eisner C, Faulhaber-Walter R, Wang Y et al. Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010; 77: 519-526
40. Eremina V, Cui S, Gerber H et al. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 2006; 17: 724-735
41. Iruela-Arispe L, Gordon K, Hugo C et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995; 147: 1715-1727
42. Kim W, Moon SO, Lee SY et al. COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. J Am Soc Nephrol 2006; 17: 2474-2483 (Pubitemid 44300963)
43. Lee S, Kim W, Moon SO et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant 2007; 22: 396-408 (Pubitemid 46189882)
44. Gordon MS, Cunningham D. Managing patients treated with bevaci-zumab combination therapy. Oncology 2005; 69: S25-S33
45. Izzedine H, Rixe O, Billemont B et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007; 50: 203-218 (Pubitemid 47095077)
46. Doubler S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030 (Pubitemid 36384273)
47. Ichinose K, Maeshima Y, Yamamoto Yet al. 2-(8-hydroxy-6-methoxy-1-oxo-1H- 2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 2006; 55: 1232-1242 (Pubitemid 44195359)
48. Advani A, Kelly DJ, Advani SL et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci USA 2007; 104: 14448-14453 (Pubitemid 350003281)
49. Ku CH, White KE, Dei Cas A et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-2833
50. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820 (Pubitemid 34000785)
51. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diab Care 2003; 26: 1589-1596 (Pubitemid 36929196)
52. Higgins DF, Kimura K, Bernhardt WM et al. Hypoxia promotes fibro-genesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820 (Pubitemid 350224091)